These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 35632821)
21. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. Hosoki K; Chakraborty A; Sur S J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257 [TBL] [Abstract][Full Text] [Related]
22. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234 [TBL] [Abstract][Full Text] [Related]
23. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840 [TBL] [Abstract][Full Text] [Related]
24. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
25. A potent virucidal activity of functionalized TiO León-Gutiérrez G; Elste JE; Cabello-Gutiérrez C; Millán-Pacheco C; Martínez-Gómez MH; Mejía-Alvarez R; Tiwari V; Mejía A Appl Microbiol Biotechnol; 2022 Sep; 106(18):5987-6002. PubMed ID: 35951081 [TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results. D'Ascanio L; Vitelli F; Cingolani C; Maranzano M; Brenner MJ; Di Stadio A Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4156-4162. PubMed ID: 34156697 [TBL] [Abstract][Full Text] [Related]
27. The structural basis of accelerated host cell entry by SARS-CoV-2†. Seyran M; Takayama K; Uversky VN; Lundstrom K; Palù G; Sherchan SP; Attrish D; Rezaei N; Aljabali AAA; Ghosh S; Pizzol D; Chauhan G; Adadi P; Mohamed Abd El-Aziz T; Soares AG; Kandimalla R; Tambuwala M; Hassan SS; Azad GK; Pal Choudhury P; Baetas-da-Cruz W; Serrano-Aroca Á; Brufsky AM; Uhal BD FEBS J; 2021 Sep; 288(17):5010-5020. PubMed ID: 33264497 [TBL] [Abstract][Full Text] [Related]
28. Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. Sanna V; Satta S; Hsiai T; Sechi M Eur J Med Chem; 2022 Mar; 231():114121. PubMed ID: 35114539 [TBL] [Abstract][Full Text] [Related]
29. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. Li Z; Wu J; Zhou J; Yuan B; Chen J; Wu W; Mo L; Qu Z; Zhou F; Dong Y; Huang K; Liu Z; Wang T; Symmes D; Gu J; Sho E; Zhang J; Chen R; Xu Y mBio; 2021 Oct; 12(5):e0254221. PubMed ID: 34634931 [TBL] [Abstract][Full Text] [Related]
30. Potential inhibitors of SARS-CoV-2: recent advances. Jamalipour Soufi G; Iravani S J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953 [TBL] [Abstract][Full Text] [Related]
31. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection. Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB Front Immunol; 2022; 13():811430. PubMed ID: 35250984 [TBL] [Abstract][Full Text] [Related]
32. The Basal Pharmacology of Palmitoylethanolamide. Rankin L; Fowler CJ Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114698 [TBL] [Abstract][Full Text] [Related]
33. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses. Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054 [TBL] [Abstract][Full Text] [Related]
34. Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets. Kamel NA; El Wakeel LM; Aboshanab KM Viral Immunol; 2021 Oct; 34(8):510-521. PubMed ID: 34018828 [TBL] [Abstract][Full Text] [Related]
35. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Sternberg A; McKee DL; Naujokat C Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679 [TBL] [Abstract][Full Text] [Related]
36. Broad-spectrum antiviral activity of Spatholobus suberectus Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses. Liu Q; Kwan KY; Cao T; Yan B; Ganesan K; Jia L; Zhang F; Lim C; Wu Y; Feng Y; Chen Z; Liu L; Chen J Phytother Res; 2022 Aug; 36(8):3232-3247. PubMed ID: 35943221 [TBL] [Abstract][Full Text] [Related]
37. Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. Toelzer C; Gupta K; Berger I; Schaffitzel C Acta Crystallogr D Struct Biol; 2023 Feb; 79(Pt 2):111-121. PubMed ID: 36762857 [TBL] [Abstract][Full Text] [Related]
39. Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. Heffernan KS; Ranadive SM; Jae SY Med Hypotheses; 2020 Oct; 143():110197. PubMed ID: 33017906 [TBL] [Abstract][Full Text] [Related]
40. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]